



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Tsann-Long Su et al. Art Unit : Unknown
Serial No. : 10/630,343 Examiner : Unknown
Filed : July 30, 2003
Title : 5-(9-ACRIDINYLAMINO)-TOLUIDINE COMPOUNDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Copies of the references listed on the attached form PTO-1449 are enclosed.

This statement is being filed within three months of the filing date of the application.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 8-28-03

Y. Rocky Tsao
Y. Rocky Tsao
Reg. No. 34,053

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20708942.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

August 28, 2003
Date of Deposit

Diane M. Miles
Signature

Diane M. Miles
Typed or Printed Name of Person Signing Certificate



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08919-094001	Application No. 10/630,343
		Applicant Tsann-Long Su et al.	
		Filing Date July 30, 2003	Group Art Unit

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)


(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,939,428	08/17/1999	Su et al.	514	297	
	AB	5,354,864	10/11/1994	Watanabe et al.	546	106	
	AC						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AD							
	AE							
	AF							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AG	Zaimen A. Arlin, "Current Status of Amsacrine (AMSA) Combination Chemotherapy Programs in Acute Leukemia", <u>Cancer Treatment Reports</u> , Vol 67, No. 11, pp. 967-970 (November 1983)
	AH	Bruce C. Baguley, et al., "Potential Antitumor Agents. 34. Quantitative Relationships between DNA Binding and Molecular Structure for 9-Anilinoacridines Substituted in the Anilino Ring", <u>J. Med. Chem.</u> , Vol. 24, pp. 170-177 (1981)
	AI	Bruce C. Baguley, et al., "Synthesis, Antitumor Activity, and DNA Binding Properties of a New Derivative of Amsacrine, N-5-Dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4-acridinecarboxamide ^{1,2} ", <u>Cancer Research</u> , Vol. 44, pp. 3245-3251 (August, 1984)
	AJ	B.F. Cain et al., "The Experimental Antitumour Properties of Three Congeners of the Acridylmethanesulphonanilide (AMSA) Series" <u>European Journal of Cancer</u> , Vol. 10, No. 8, pp. 539-549 (August 1974)
	AK	Bruce F. Cain et al., "Potential Antitumor Agents. 16. 4'-(Acridin-9-ylamino) methanesulfonanilides", <u>Journal of Medicinal Chemistry</u> , Vol. 18, No. 11, pp. 1110-1117 (1975)
	AL	Bruce F. Cain et al., "Potential Antitumor Agents. 14. Acridylmethanesulfonanilides", <u>Journal of Medicinal Chemistry</u> , Vol. 17, No. 9, pp. 922-930 (1974)
	AM	William A. Denny et al., "Potential Antitumor Agents. 36. Quantitative Relationships between Experimental Antitumor Activity, Toxicity, and Structure for the General Class of 9-Anilinoacridine Antitumor Agents", <u>J. Med. Chem.</u> , Vol. 25, pp. 276-315 (1982)
	AN	Gordon W. Rewcastle et al., "Potential Antitumor Agents. 46. Structure-Activity Relationships for Acridine Monosubstituted Derivatives of the Antitumor Agent N-[2-(Dimethylamino)ethyl]-9-aminoacridine-4-carboxamide", <u>J. Med. Chem.</u> , Vol. 29, pp. 472-477 (1986)
	AO	I. G. C. Robertson et al., "Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse", <u>Xenobiotica</u> , Vol. 22, No. 6, pp. 657-669 (1992)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 08919-094001	Application No. 10/630,343
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Tsann-Long Su et al.	
		Filing Date July 30, 2003	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	BA	L. G. C. Robertson et al., "Involvement of Glutathione in the Metabolism of the Anilinoacridine Antitumour Agents CI-921 and Amsacrine", <u>Drug Metabolism and Drug Interactions</u> , Vol. VI, No. 3-4, pp. 371-381 (1988)
	BB	T. D. Sakore et al., "Visualization of Drug-Nucleic Acid Interactions at Atomic Resolution", <u>J. Mol. Biol.</u> , Vol. 135, pp. 763-785 (1979)
	BC	D. D. Shoemaker et al., "Identification of the Principal Biliary Metabolite of 4'-(9-Acridinylamino)Methanesulfon-m-Anisidide in Rats", <u>Drug Metabolism and Disposition</u> , Vol. 10, No. 1, pp. 35-39 (Jan/Feb 1982)
	BD	D. D. Shoemaker et al., "Metabolism of 4'-(9-Acridinylamino)methanesulfon-m-anisidide by Rat Liver Microsomes", <u>Cancer Research</u> , Vol. 44, pp. 1939-1945 (May 1984)
	BE	Su et al., "A new class of water soluble acridinyl derivatives that exhibit Topo II mediated DNA cleavage and antitumor efficacy", <u>Am. Cancer Res.</u> , 368, 2190 (1994) from the abstract book of the 85 th meeting of the American Association for Cancer Research (April 10-13, 1994)
	BF	Su et al., "9-Substituted Acridine Derivatives with Long Half-Life and Potent Antitumor Activity: Synthesis and Structure - Activity Relationships", <u>J. Med. Chem.</u> , Vol. 38, pp. 3226-3235 (1995)
	BG	Su et al., "Synthesis and Structure - Activity Relationships of Potential Anticancer Agents: Alkylcarbamates of 3-(9-Acridinylamino)-5-hydroxymethylaniline", <u>J. Med. Chem.</u> , Vol. 42, pp. 4741-4748 (1999)
	BH	Su et al., "Development of 3-(9-Acridinylamino)-5-hydroxymethyl-anilines as Potential Topoisomerase II-Mediated Anticancer Agents", <u>Cancer Detect. Prev. 2000/Suppl.</u> , Vol. 24, pp. 211 (2000)
	BI	
	BJ	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	